The Pharmaletter

Nimbus Therapeutics

A private, clinical-stage biotechnology company based in Cambridge, Massachusetts. The company operates as a small-molecule R&D organization, running clinical development through external trial networks and advancing programs in oncology, immunology, and metabolic disease.

Founding and History

Nimbus was founded in 2009 to apply structure-based and computation-enabled drug discovery to validated targets. The company has used partnering to monetize programs and recycle capital into its internal pipeline, including the 2022 transaction in which Takeda agreed to acquire Nimbus’ allosteric TYK2 inhibitor program, later renamed TAK-279. In March 2025, Nimbus appointed Abbas Kazimi as chief executive officer. In January 2026, Nimbus expanded its metabolic discovery activity through a new multi-year research and licensing collaboration with Eli Lilly focused on AI-enabled oral therapies for obesity and related metabolic diseases.

Therapy Areas and Focus

Nimbus’ disclosed portfolio spans three areas:

Oncology, with programs targeting tumor-intrinsic vulnerabilities and immuno-oncology mechanisms
Immunology and inflammation, including prior late-stage activity in TYK2 inhibition via its partnered program
Metabolic disease, supported by discovery collaborations and internal technology investment

Technology Platforms and Modalities

Nimbus develops oral small molecules using a design-led approach that combines computational chemistry, structure-based methods, and translational strategy to build selective inhibitors against defined targets. The company’s recent external collaborations highlight continued investment in AI-enabled discovery workflows, particularly in metabolic disease.

Key Personnel

Abbas Kazimi serves as chief executive officer. The company has disclosed senior leadership across discovery, translational medicine, clinical development, and corporate functions, including a dedicated oncology leadership structure.

Strategic Partnerships

Nimbus has used partnerships both to advance assets and to fund internal R&D. Recent and notable transactions include:

Eli Lilly collaboration announced January 2026 to discover AI-enabled oral medicines for obesity and metabolic disease, structured with upfront and milestone economics plus royalties
Takeda acquisition of Nimbus’ allosteric TYK2 inhibitor program (TAK-279), providing Nimbus with significant upfront proceeds and potential additional milestones
Earlier collaborations supporting platform and portfolio expansion, including ongoing work with partners in discovery and development

FAQ Section

Nimbus is a small-molecule company built around design-driven drug discovery, using structure-based and computational methods to generate selective oral medicines against defined targets.

Nimbus operates across oncology, immunology and inflammation, and metabolic disease, selecting programs where target biology is considered clinically relevant and where selectivity can be a differentiator.

Nimbus’ disclosed clinical-stage oncology programs include:

NDI-101150, an HPK1 inhibitor in Phase I/II evaluation in advanced solid tumors
NDI-219216, a WRN inhibitor in Phase I/II development for MSI-H tumors, with dose escalation reported complete in December 2025

In immunology, Nimbus’ most advanced historical asset was its allosteric TYK2 inhibitor program, now owned by Takeda as TAK-279.

In January 2026, Nimbus announced a new multi-year research and licensing collaboration with Eli Lilly to develop AI-enabled oral therapies for obesity and metabolic disease. In December 2025, Nimbus reported completion of dose escalation in its Phase I/II study of NDI-219216. In March 2025, Nimbus appointed Abbas Kazimi as chief executive officer.

Nimbus has publicly presented early clinical updates for its HPK1 inhibitor program and has provided trial-progress disclosures for its WRN inhibitor program, including dose-escalation completion for NDI-219216 in late 2025. For the former TYK2 program, Nimbus previously reported Phase II data in psoriasis prior to the Takeda transaction.

Near-term milestones are tied to continued Phase I/II oncology development for NDI-101150 and NDI-219216, including expansion cohorts and selection of next-stage study designs as data mature. For partnered metabolic discovery with Lilly and the TYK2 program with Takeda, development and regulatory timelines are governed by partner-led plans and option structures.

Nimbus is led by an executive team with experience spanning computational chemistry, translational medicine, and clinical development, with recent leadership transition to CEO Abbas Kazimi and an operating model that combines internal pipeline execution with selective partnering.

Want to Update your Company's Profile?